A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening
- PMID: 11009086
- DOI: 10.1002/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O
A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening
Abstract
Knowledge of the immunodominant responses to Epstein-Barr Virus (EBV) and human cytomegalovirus (HCMV) should help to generate cytotoxic T cell lines to these herpesviruses. Here we report on the analysis of CD8 T cell responses to EBV and HCMV in the blood of kidney transplant recipients undergoing viral reactivation (n = 16) and in healthy virus carriers (n = 10). We used a transient COS transfection assay that permits semi-quantitative estimation of CD8+ T cell responses against a larger number of HLA/viral protein combinations within polyclonal T cell lines and thus allows a rapid identification of major epitopes. From the comparison of these responses to those that we previously described in the synovial fluid of patients suffering from various forms of chronic arthritis (n = 32), it appears that EBV-specific T cells are mainly directed against a restricted set of immunodominant epitopes, primarily generated during the early lytic cycle and that both IE1 and pp65 are targets of the anti-HCMV response. We suggest that this method could be generally applied to the rapid identification of immunodominant T cell epitopes in viral and tumor immunity, and could help selecting HLA-peptide complexes that could be used to detect and sort specific T cell populations.
Similar articles
-
Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-Transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells.Hum Immunol. 2004 May;65(5):514-22. doi: 10.1016/j.humimm.2004.02.018. Hum Immunol. 2004. PMID: 15172452
-
Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity.Protein Expr Purif. 2008 Sep;61(1):22-30. doi: 10.1016/j.pep.2008.05.001. Epub 2008 May 14. Protein Expr Purif. 2008. PMID: 18539483
-
Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.J Med Virol. 2004 Apr;72(4):635-45. doi: 10.1002/jmv.20023. J Med Virol. 2004. PMID: 14981767
-
Immunodominant CD8 T cell response to Epstein-Barr virus.Biomed Pharmacother. 2001 Sep;55(7):373-80. doi: 10.1016/s0753-3322(01)00082-8. Biomed Pharmacother. 2001. PMID: 11669500 Review.
-
Epstein-Barr virus and rheumatoid arthritis.Rev Rhum Engl Ed. 1998 Jun;65(6):365-8. Rev Rhum Engl Ed. 1998. PMID: 9670326 Review. No abstract available.
Cited by
-
Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study.Front Immunol. 2023 Oct 30;14:1251593. doi: 10.3389/fimmu.2023.1251593. eCollection 2023. Front Immunol. 2023. PMID: 37965339 Free PMC article. Clinical Trial.
-
AIM™ platform: A new immunotherapy approach for viral diseases.Front Med (Lausanne). 2022 Dec 23;9:1070529. doi: 10.3389/fmed.2022.1070529. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36619639 Free PMC article.
-
A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice.PLoS Pathog. 2022 Jun 23;18(6):e1010403. doi: 10.1371/journal.ppat.1010403. eCollection 2022 Jun. PLoS Pathog. 2022. PMID: 35737741 Free PMC article.
-
Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL.PLoS Pathog. 2022 Apr 22;18(4):e1010206. doi: 10.1371/journal.ppat.1010206. eCollection 2022 Apr. PLoS Pathog. 2022. PMID: 35452490 Free PMC article.
-
Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction.Vaccines (Basel). 2021 Nov 7;9(11):1290. doi: 10.3390/vaccines9111290. Vaccines (Basel). 2021. PMID: 34835222 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
